Holen Sie sich die Stockscreener-App
52.27
32.36%
12.78
Schlusskurs vom Vortag:
$39.49
Offen:
$52.31
24-Stunden-Volumen:
50.97M
Relative Volume:
21.33
Marktkapitalisierung:
$2.70B
Einnahmen:
$190.41M
Nettoeinkommen (Verlust:
$20.48M
KGV:
234.59
EPS:
0.2228
Netto-Cashflow:
$46.66M
1W Leistung:
+71.71%
1M Leistung:
+31.73%
6M Leistung:
-10.57%
1J Leistung:
-22.54%
1-Tages-Spanne:
$52.15
$52.38
1-Wochen-Bereich:
$30.90
$52.38
52-Wochen-Spanne:
$29.43
$90.32
Soleno Therapeutics Inc Stock (SLNO) Company Profile
Firmenname
Soleno Therapeutics Inc
Sektor
Branche
Telefon
650-213-8444
Adresse
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA
Compare SLNO vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SLNO
Soleno Therapeutics Inc
|
52.27 | 2.04B | 190.41M | 20.48M | 46.66M | 0.2228 |
VRTX
Vertex Pharmaceuticals Inc
|
436.18 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
758.56 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
747.89 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.16 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
164.78 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-18 | Eingeleitet | Wolfe Research | Outperform |
| 2025-10-07 | Eingeleitet | Goldman | Buy |
| 2025-08-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-06-23 | Eingeleitet | TD Cowen | Buy |
| 2025-03-05 | Fortgesetzt | Stifel | Buy |
| 2024-12-02 | Bestätigt | Robert W. Baird | Outperform |
| 2024-12-02 | Bestätigt | Stifel | Buy |
| 2024-09-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-10 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-02-05 | Eingeleitet | Piper Sandler | Overweight |
| 2024-01-23 | Eingeleitet | Stifel | Buy |
| 2023-11-21 | Fortgesetzt | Guggenheim | Buy |
| 2020-09-29 | Eingeleitet | Guggenheim | Buy |
| 2020-01-10 | Eingeleitet | Craig Hallum | Buy |
| 2019-12-23 | Eingeleitet | Oppenheimer | Outperform |
| 2018-02-13 | Bestätigt | Maxim Group | Buy |
Alle ansehen
Soleno Therapeutics Inc Aktie (SLNO) Neueste Nachrichten
Shareholder Alert: The Ademi Firm investigates whether Soleno Therapeutics Inc.'s Transaction with Neurocrine is Fair to Public Shareholders - PR Newswire
Soleno Therapeutics jumps on $2.9B all-cash buyout deal at $53/share - Quiver Quantitative
Soleno Therapeutics' (SLNO) Neutral Rating Reaffirmed at Cantor Fitzgerald - MarketBeat
Soleno Therapeutics Stock Skyrockets 33% After Neurocrine Biosciences Announces Acquisition Deal - TIKR.com
Soleno Therapeutics shares jump nearly 40% on $2.9 billion takeout deal | 2026-04-06 | Investing News - Stockhouse
Soleno Therapeutics, Playtika Holding And Other Big Stocks Moving Higher On Monday - Benzinga
Neurocrine, eying ‘blockbuster in the making,’ strikes its largest-ever M&A deal with $2.9B Soleno buyout - Fierce Pharma
Neurocrine Biosciences to buy Soleno Therapeutics in $2.9B deal - Axios
Neuroendocrine Bioscience spends 2.9 billion US dollars to acquire Soleno and enters the metabolic disease field. - 富途牛牛
Neurocrine Enters $2.9 Billion Agreement to Acquire Soleno Therapeutics - pharmexec.com
Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. - Barron's
Neurocrine to Buy Soleno Therapeutics for $2.9 Billion - Bloomberg.com
SLNO Stock Alert: Halper Sadeh LLC is Investigating Whether Soleno Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders - marketscreener.com
Neurocrine Biosciences to acquire Soleno Therapeutics in $2.9B deal - Yahoo! Finance Canada
Soleno Therapeutics (SLNO) still appears attractive despite slower US launch ramp projections - MSN
Neurocrine Biosciences to acquire Soleno Therapeutics for $2.9 billion - MLex
Neurocrine expands into metabolic diseases with $2.9 billion Soleno buyout - PharmaLive
Oppenheimer’s Bold Forecast: Soleno Sees $80 Price Target Amid Slower Vykat XR Launch - timothysykes.com
Neurocrine Biosciences to Acquire Soleno Therapeutics in $2.9 Billion Deal - marketscreener.com
Soleno Therapeutics (SLNO) Stock Jumps 30% on Neurocrine $2.5B Buyout Report - MEXC
Neurocrine Biosciences Close to $2.5B Acquisition of Soleno Therapeutics - Meyka
Neurocrine Biosciences Agrees to Acquire Soleno Therapeutics for $2.9B - Contract Pharma
Neurocrine Nabs Rare Obesity Disorder Drug in ‘Surprising’ $2.9B Soleno Deal - BioSpace
Soleno Therapeutics to Be Acquired by Neurocrine Biosciences - TipRanks
Neurocrine Buys Soleno To Tap High-Growth Rare Disease Market - Benzinga
Neurocrine to Buy Soleno for $2.9 Billion - wsj.com
These Stocks Are Today’s Movers: Intel, Micron, Tesla, Strategy, Netflix, Soleno, and More - Barron's
Neurocrine to Acquire Soleno, Expanding Rare Disease Portfolio - TipRanks
Breakfast News: Soleno Soars 30% On Buyout Talk - The Motley Fool
Neurocrine Biosciences to Acquire Soleno Therapeutics for $2.9 Billion in Cash - marketscreener.com
Soleno to Be Acquired by Neurocrine in $53-Per-Share Tender Offer - TradingView
Neurocrine Biosciences (NBIX) agrees to buy Soleno (SLNO) for $53/share - Stock Titan
Neurocrine to buy Soleno (NASDAQ: SLNO) in $2.9B all-cash deal - Stock Titan
Neurocrine Biosciences to Acquire Soleno Therapeutics in $53-Per-Share Tender Offer and Merger - TradingView
Neurocrine Biosciences: $2.9 Billion Acquisition Of Soleno Therapeutics To Expand Rare Disease Portfolio - Pulse 2.0
Neurocrine (NBIX) to acquire Soleno in $2.9B rare-disease portfolio deal - Stock Titan
Neurocrine will pay $2.9B for Soleno and its Prader-Willi medicine - Endpoints News
Stocks making the biggest moves premarket: Netflix, Soleno Therapeutics, Strategy & more - CNBC
SLNO Stock Soars Over 39% — What’s Fueling The Rally? - Stocktwits
Neurocrine to acquire Soleno Therapeutics, expanding its endocrinology and rare disease portfolio - marketscreener.com
Neurocrine To Acquire Soleno Therapeutics, Expanding Its Endocrinology And Rare Disease Portfolio - TradingView
Neurocrine to buy Soleno Therapeutics for $2.9 billion By Reuters - Investing.com
Neurocrine to buy Soleno Therapeutics for $2.9B - Breakingthenews.net
Neurocrine to acquire Soleno Therapeutics for $2.9 billion - Investing.com
Neurocrine nears over $2.5B deal to acquire Soleno Therapeutics, FT reports - TipRanks
Soleno Therapeutics Slides Despite Multi-Billion Buyout Talks - TipRanks
Soleno Therapeutics (SLNO) Stock Soars 30% on $2.5B Neurocrine Acquisition News - Blockonomi
These Stocks Are Today's Movers: Intel, Micron, Paramount, Strategy, Soleno Therapeutics, and More -- Barrons.com - Moomoo
M&A News: Soleno Therapeutics Stock (SLNO) Surges 28% as Neurocrine Biosciences Lines up $2.5B Deal - TipRanks
SG Americas Securities LLC Increases Position in Soleno Therapeutics, Inc. $SLNO - MarketBeat
SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit - Cherokee Tribune
Finanzdaten der Soleno Therapeutics Inc-Aktie (SLNO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Soleno Therapeutics Inc-Aktie (SLNO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Huang Michael F. | Sr. VP of Clinical Development |
Mar 27 '26 |
Sale |
30.44 |
6,582 |
200,365 |
39,823 |
1.90%
1.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):